This week’s episode of “The Topline” takes a deep dive into the biopharmaceutical industry’s fourth quarter performance and how the industry fared throughout 2025.
When the world’s 25 largest biopharmaceutical companies announced their financial results, attention quickly turned to their outlook for 2026. Only five pharmaceutical companies expect higher growth than in 2025, and some predict a decline in sales.
One of the most surprising forecasts comes from Novo Nordisk, which expects a significant decline in sales. Several other companies are also facing the loss of patent protection for blockbuster drugs and are expected to see lower revenues or slower growth.
Fierce Pharma’s Kevin Dunleavy and Eric Sagonowsky discuss trends emerging from fourth quarter earnings and how industry performance compares to previous quarters. They also examine the growing GLP-1 competition between Novo Nordisk and Eli Lilly and how the companies appear to be heading in opposite directions.
